{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T01:14:07Z","timestamp":1783300447910,"version":"3.54.6"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"International Genomics Consortium"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-51989-8","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:16:21Z","timestamp":1777925781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structure-guided identification and biological evaluation of reversible EGFR C797S inhibitors"],"prefix":"10.1038","volume":"16","author":[{"given":"Glen J.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Mallery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhan L.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"51989_CR1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129\u20132139 (2004).","journal-title":"N. Engl. J. Med."},{"key":"51989_CR2","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez, J. G., J\u00e4nne, P. A. & Lee, J. C. others. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497\u20131500 (2004).","journal-title":"Science"},{"key":"51989_CR3","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi, S. et al. EGFR mutation and resistance of non\u2013small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786\u2013792 (2005).","journal-title":"N. Engl. J. Med."},{"key":"51989_CR4","doi-asserted-by":"publisher","unstructured":"Yun, C-H. et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences [Internet]. Proceedings of the National Academy of Sciences; [cited 2026 Jan 13];105:2070\u20135. Available from: https:\/\/www.pnas.org\/doi\/ (2008). https:\/\/doi.org\/10.1073\/pnas.0709662105","DOI":"10.1073\/pnas.0709662105"},{"key":"51989_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok, T. S. et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl. J. Med. 376, 629\u2013640 (2017).","journal-title":"N Engl. J. Med."},{"key":"51989_CR6","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress, K. S., Paweletz, C. P. & Felip, E. others. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non\u2013small cell lung cancer. Nat. Med. 21, 560\u2013562 (2015).","journal-title":"Nat. Med."},{"key":"51989_CR7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/j.jtho.2019.07.016","volume":"14","author":"D Rangachari","year":"2019","unstructured":"Rangachari, D. et al. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M\/C797S in Preclinical Models and Clinical Samples. J. Thorac. Oncol. 14, 1995\u20132002 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"51989_CR8","doi-asserted-by":"publisher","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","volume":"65","author":"MS Eno","year":"2022","unstructured":"Eno, M. S. et al. Discovery of BLU-945, a potent and selective reversible EGFR mutant inhibitor with activity against C797S. J. Med. Chem. 65, 9662\u20139677 (2022).","journal-title":"J. Med. Chem."},{"key":"51989_CR9","doi-asserted-by":"publisher","unstructured":"Le, X. et al. Abstract C151: BLU-451 is a CNS-penetrant, wild-type-sparing EGFR inhibitor with broad coverage of uncommon EGFR mutations across structure-based subsets. Mol Cancer Ther [Internet]. [cited 2026 Jan 13];22:C151. (2023). Available from: https:\/\/doi.org\/10.1158\/1535-7163.TARG-23-C151","DOI":"10.1158\/1535-7163.TARG-23-C151"},{"key":"51989_CR10","doi-asserted-by":"crossref","unstructured":"Lucas, M. et al. BDTX-1535, a fourth generation EGFR inhibitor, targeting intrinsic and acquired resistance mutations in NSCLC. European Journal of Cancer [Internet]. Elsevier; [cited 2026 Jan 13];174:S22. (2022). Available from: https:\/\/www.ejcancer.com\/article\/S0959-8049(22)00862-0\/abstract","DOI":"10.1016\/S0959-8049(22)00862-0"},{"key":"51989_CR11","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho, B. C. et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl. J. Med. 391, 1486\u20131498 (2024).","journal-title":"N Engl. J. Med."},{"key":"51989_CR12","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","volume":"393","author":"JCH Yang","year":"2025","unstructured":"Yang, J. C. H. et al. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl. J. Med. 393, 1681\u20131693 (2025).","journal-title":"N Engl. J. Med."},{"key":"51989_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molcel.2011.03.004","volume":"42","author":"N Jura","year":"2011","unstructured":"Jura, N. et al. Catalytic control in the EGF receptor. Mol. Cell. 42, 9\u201322 (2011).","journal-title":"Mol. Cell"},{"key":"51989_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1741-7007-9-71","volume":"9","author":"JD Durrant","year":"2011","unstructured":"Durrant, J. D. & McCammon, J. A. Molecular dynamics simulations and drug discovery. BMC Biol. 9, 71 (2011).","journal-title":"BMC Biol."},{"key":"51989_CR15","unstructured":"Engelman, J. A. et al. MET amplification leads to gefitinib resistance. Proceedings of the National Academy of Sciences USA. ;104:20932\u20137. (2007)."},{"key":"51989_CR16","doi-asserted-by":"publisher","first-page":"46265","DOI":"10.1074\/jbc.M207135200","volume":"277","author":"J Stamos","year":"2002","unstructured":"Stamos, J., Sliwkowski, M. X. & Eigenbrot, C. Structure of the EGFR kinase domain. J. Biol. Chem. 277, 46265\u201346272 (2002).","journal-title":"J. Biol. Chem."},{"key":"51989_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/978-1-59745-177-2_19","volume":"443","author":"GM Morris","year":"2008","unstructured":"Morris, G. M. & Lim-Wilby, M. Molecular docking. Methods Mol. Biol. 443, 365\u2013382 (2008).","journal-title":"Methods Mol. Biol."},{"key":"51989_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/CCO.0b013e328011a25f","volume":"19","author":"M Warmuth","year":"2007","unstructured":"Warmuth, M., Kim, S., Gu, X., Xia, G. & Adri\u00e1n, F. Ba\/F3 cells and their use in kinase drug discovery. Curr. Opin. Oncol. 19, 55\u201360 (2007).","journal-title":"Curr. Opin. Oncol."},{"key":"51989_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0022-1759(93)90011-U","volume":"160","author":"SP Crouch","year":"1993","unstructured":"Crouch, S. P., Kozlowski, R., Slater, K. J. & Fletcher, J. ATP bioluminescence as a measure of cell proliferation. J. Immunol. Methods. 160, 81\u201388 (1993).","journal-title":"J. Immunol. Methods"},{"key":"51989_CR20","doi-asserted-by":"publisher","first-page":"175883592412806","DOI":"10.1177\/17588359241280689","volume":"16","author":"SM Lim","year":"2024","unstructured":"Lim, S. M. et al. BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer. Ther. Adv. Med. Oncol. 16, 17588359241280689 (2024).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"51989_CR21","unstructured":"Le, X. others. Preclinical characterization of BLU-451, a brain-penetrant fourth-generation EGFR inhibitor. Journal of Thoracic Oncology. ;18:987\u201399. (2023)."},{"key":"51989_CR22","doi-asserted-by":"publisher","unstructured":"Spira, A. I. et al. Phase 1\/2 study of BLU-451, a central nervous system (CNS) penetrant, small molecule inhibitor of EGFR, in incurable advanced cancers with EGFR exon 20 insertion (ex20ins) mutations. J Clin Oncol [Internet]. Wolters Kluwer; [cited 2026 Jan 13];40:TPS9155\u2013TPS9155. (2022). Available from: https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS9155","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9155"},{"key":"51989_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/17425255.2016.1229303","volume":"13","author":"A Rowland","year":"2017","unstructured":"Rowland, A. et al. Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. Expert Opin. Drug Metab. Toxicol. 13, 31\u201349 (2017).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"51989_CR24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/msj.20193","volume":"77","author":"JM Gallo","year":"2010","unstructured":"Gallo, J. M. Pharmacokinetic\/ pharmacodynamic-driven drug development. Mt. Sinai J. Med. 77, 381\u2013388 (2010).","journal-title":"Mt. Sinai J. Med."},{"key":"51989_CR25","first-page":"125","volume":"386","author":"LV Sequist","year":"2022","unstructured":"Sequist, L. V. et al. Amivantamab in EGFR-mutant non\u2013small-cell lung cancer after progression on osimertinib. N. Engl. J. Med. 386, 125\u2013137 (2022).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51989-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51989-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51989-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:14:22Z","timestamp":1783296862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51989-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51989"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51989-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following competing interests. GJW has served as a paid consultant for Bantam Pharmaceutical\u00a0(stock options and travel support), mbiomics\u00a0(stock options and travel support), Angiex (stock options and travel support), Imaging Endpoints II, International Genomics Consortium, Maverix Medical, Quibim (stock options), SUN Pharma, Kymera, Accent Therapeutics, and is an unpaid consultant for Avenio AI. GJW has employment and other business ownership interests with MiRanostics Consulting. GJW holds equity interests in Agenus, Circulogene, and Vivia Oncology. DWM has an employment interest in the International Genomics Consortium, has an employment and equity interest in Maverix Medical, holds an equity interest in Vivia Oncology and has an equity interest at Reference Medicine. JCL and NLT served as paid scientific advisors for International Genomics Consortium.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were conducted in accordance with institutional guidelines and approved protocols, and were performed by accredited contract research organizations in compliance with applicable ethical regulations. No human subjects were involved in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"20606"}}